Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYTOKINETICS INCCYTK · Entity 3528 | Director | July 15, 2026 | July 16, 2026 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | August 03, 2017 | August 07, 2017 |
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | August 14, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYTOKINETICS INC
Report date July 15, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,434 |
Reported balance
After 2026-07-15 transaction · row 1
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 151 · Balance 10,434 F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.
Sarepta Therapeutics, Inc.
Report date August 03, 2017 · Filed August 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,229 |
Ending reported balance
After 2017-08-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-03 · Exercise / conversion · Acquired 35,461 · Balance 87,932 F1: Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2017-08-03 · Tax withholding · Disposed 16,703 · Balance 71,229 F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-03 · Exercise / conversion · Disposed 35,461 · Balance 0 F1: Restricted stock units convert into common stock on a one-for-one basis. F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: Shares were withheld by the Company to satisfy tax withholding obligations related to a vesting of restricted stock units granted on March 3, 2017.
F3: On March 3, 2017, the reporting person was granted restricted stock units that vest based on the Company's satisfaction of certain performance criteria. The first performance criterion was met on August 3, 2017, resulting in vesting of 50% of such restricted stock units.
Stoke Therapeutics, Inc.
Report date August 14, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,557 |
Ending reported balance
After 2026-08-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-14 · Exercise / conversion · Acquired 26,250 · Balance 137,124 Row 2 · 2026-08-18 · Sale · Disposed 11,930 · Balance 125,194 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Row 3 · 2026-08-18 · Sale · Disposed 637 · Balance 124,557 F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-08-14 | Direct | 0 |
Reported balance
After 2026-08-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-14 · Exercise / conversion · Disposed 26,250 · Balance 0 F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock. F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.40 to $32.36 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.44 to $32.54 per share, inclusive.
F4: Each performance stock unit represents a right to receive one share of the Issuer's common stock.
F5: Achievement of this performance stock unit award was certified on August 14, 2025. Pursuant to the terms of the award agreement between the reporting person and the Issuer, half the award vested on August 14, 2025 and the remainder vests on August 14, 2026, subject to the reporting person's continued service to the Issuer on the relevant vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 6,692 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.48 · Expires 2033-06-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.03 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 22,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.82 · Expires 2030-05-14 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 11,323 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2029-08-27 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-02-27 · Disposition to issuer · Disposed 9,534 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2024 Filed Jun 7, 2024 20:42 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 159,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001415889-24-016010 · form4-06072024_080631.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,000 Underlying: Common Stock · 159,000 shares Expires 2034-03-26 F1 · derivative.exercise_date: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 11,150 | $6.10 | $67,999.39 |
DisclosureSEC source: 0001415889-24-008683 · form4-03202024_120318.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,350 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008683 · form4-03202024_120318.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,500 Underlying: Common Stock · 35,500 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F4 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 35,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008683 · form4-03202024_120318.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 21:23 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 148 | $84.12 | $12,449.76 |
DisclosureSEC source: 0001127602-24-000426 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,317 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $84.12, representing the closing stock price of the Issuer's common stock on January 2, 2024. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 25,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057396 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,908 Underlying: Common Stock · 25,908 shares Expires 2025-12-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: 21,591 restricted stock units will vest on December 1, 2024 and 4,317 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 200,800 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057396 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,800 shares Expires 2031-03-01 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 200,800 shares of Common Stock of the Issuer and in exchange issued to the reporting person 25,908 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 448 | $27.88 | $12,490.24 |
DisclosureSEC source: 0001127602-23-025179 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,169 F1 · shares: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $27.88, representing the Issuer's closing stock price on October 2, 2023. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 374 | $33.36 | $12,476.64 |
DisclosureSEC source: 0001127602-23-020054 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,721 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $33.36, representing the Issuer's closing stock price on July 3, 2023. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:04 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.48 | $0.00 |
DisclosureSEC source: 0001599901-23-000047 · wk-form4_1687291452.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:54 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001127602-23-016171 · form4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-10 F2 · kind: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2023 and the last such installment vesting on 05/10/2024. Read SEC document |
| May 10, 2023 Filed May 18, 2023 20:54 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-016171 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,347 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2024. Read SEC document |
| April 03, 2023 Filed Apr 5, 2023 20:08 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 298 | $37.71 | $11,237.58 |
DisclosureSEC source: 0001127602-23-012548 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,347 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of director's annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $37.71, representing the closing stock price of the Issuer's common stock on April 3, 2023. Read SEC document |
| March 27, 2023 Filed Sep 8, 2023 20:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-23-048770 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602,801 Underlying: Common Stock · 20,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2023 Filed Sep 8, 2023 20:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 20,000 | $0.60 | $12,000.00 |
DisclosureSEC source: 0001209191-23-048770 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 142,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019653 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,000 Underlying: Common Stock · 142,000 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 213,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019653 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:33 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 253 | $44.35 | $11,220.55 |
DisclosureSEC source: 0001127602-23-000700 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,049 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $44.35, representing the Issuer's closing stock price on January 3, 2023. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 167,050 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001209191-22-060543 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,050 Underlying: Common Stock · 167,050 shares Expires 2032-12-06 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on January 7, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 20:21 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 220 | $51.11 | $11,244.20 |
DisclosureSEC source: 0001127602-22-023699 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,796 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $51.11, representing the closing stock price of Issuer's common stock on October 3, 2022. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (Right to Buy) · Derivative | 11,428 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001127602-22-020670 · form4.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,428 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 12, 2021. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 11,428 | $50.00 | $571,400.00 |
DisclosureSEC source: 0001127602-22-020670 · form4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,576 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 12, 2021. Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 20:01 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 11,428 | $8.75 | $99,995.00 |
DisclosureSEC source: 0001127602-22-020670 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 12, 2021. Read SEC document |
| July 01, 2022 Filed Jul 12, 2022 20:22 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 274 | $41.00 | $11,234.00 |
DisclosureSEC source: 0001127602-22-019234 · form4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,576 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares are issued at per share price of $41.00, representing the closing stock price of Issuer's common stock on July 1, 2022. Read SEC document |
| June 15, 2022 Filed Jun 18, 2022 00:49 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $12.03 | $0.00 |
DisclosureSEC source: 0001209191-22-038220 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 21:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-22-032259 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 622,801 Underlying: Common Stock · 15,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| May 25, 2022 Filed May 26, 2022 21:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 15,000 | $0.60 | $9,000.00 |
DisclosureSEC source: 0001209191-22-032259 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $37.89 | $0.00 |
DisclosureSEC source: 0001061983-22-000119 · edgardoc.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-10 F2 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/10/2022 and the last such installment vesting on 05/10/2023. Read SEC document |
| May 10, 2022 Filed May 11, 2022 22:05 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-22-000119 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,302 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/10/2023. Read SEC document |
| April 01, 2022 Filed Apr 1, 2022 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 293 | $38.38 | $11,245.34 |
DisclosureSEC source: 0001061983-22-000088 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,302 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are fully vested from the moment of grant. Shares issued at per share price of $38.38, representing the Issuer's closing stock price on April 1, 2022. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 308,000 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0001209191-22-019689 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,000 Underlying: Common Stock · 308,000 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 03, 2022 Filed Jan 4, 2022 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 244 | $46.00 | $11,224.00 |
DisclosureSEC source: 0001061983-22-000011 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,009 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $46.00, representing the Issuer's closing stock price on January 3, 2022. F2 · balance_after: Amount includes 2,009 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.61 | $0.00 |
DisclosureSEC source: 0001061983-21-000265 · edgardoc.xml · derivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | SaleCommon Stock | 15,000 | $45.00 | $675,000.00 |
DisclosureSEC source: 0001061983-21-000265 · edgardoc.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 12, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 23, 2021 Filed Dec 24, 2021 00:11 UTC | CYTOKINETICS INC CYTK · Entity 3528 | Exercise / conversionCommon Stock | 15,000 | $7.61 | $114,150.00 |
DisclosureSEC source: 0001061983-21-000265 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on November 12, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 23:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 306 | $36.74 | $11,242.44 |
DisclosureSEC source: 0001061983-21-000230 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $36.74, representing the Issuer's closing stock price on October 1, 2021. F2 · balance_after: Amount includes 1,765 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 21:31 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 63 | $19.77 | $1,245.51 |
DisclosureSEC source: 0001061983-21-000190 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.77, representing the Issuer's closing stock price on July 7, 2021. F2 · balance_after: Amount includes 1,459 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 20:45 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 476 | $20.98 | $9,986.48 |
DisclosureSEC source: 0001061983-21-000172 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,396 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $20.98, representing the Issuer's closing stock price on July 1, 2021. F2 · balance_after: Amount includes 1,396 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 00:05 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $26.09 | $0.00 |
DisclosureSEC source: 0001209191-21-041140 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The option shall vest on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $24.32 | $0.00 |
DisclosureSEC source: 0001061983-21-000142 · edgardoc.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-05-12 F3 · derivative.exercise_date: Options shall vest and become exercisable in 12 equal monthly installments, the first such installment vesting on 06/12/2021 and the last such installment vesting on 05/12/2022. Read SEC document |
| May 12, 2021 Filed May 14, 2021 00:02 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001061983-21-000142 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 F1 · kind: Comprised of restricted stock units that will vest in full and in one installment on 05/12/2022. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 21:47 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 409 | $24.44 | $9,995.96 |
DisclosureSEC source: 0001061983-21-000098 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 920 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $24.44, representing the Issuer's closing stock price on April 1, 2021. F2 · balance_after: Amount includes 920 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 21:57 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 200,800 | $0.00 Strike: $60.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017865 · doc4.xml · derivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,800 Underlying: Common Stock · 200,800 shares Expires 2031-03-01 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:17 UTC | CYTOKINETICS INC CYTK · Entity 3528 | GrantCommon Stock | 511 | $19.56 | $9,995.16 |
DisclosureSEC source: 0001061983-21-000015 · edgardoc.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511 F1 · kind: Shares issued at Reporting Person's election pursuant to Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Shares are full vested from the moment of grant. Shares issued at per share price of $19.56, representing the Issuer's closing stock price on January 4, 2021. F2 · balance_after: Amount includes 511 shares of common stock received at Reporting Person's election pursuant Issuer's stock in lieu of cash for all or part of directors' annual base retainer program. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001209191-21-000508 · doc4.xml · derivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,801 Underlying: Common Stock · 10,000 shares Expires 2028-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 30, 2020 Filed Jan 4, 2021 23:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 10,000 | $0.60 | $6,000.00 |
DisclosureSEC source: 0001209191-21-000508 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2020 Filed Dec 19, 2020 02:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,194 | $60.00 | $311,640.00 |
DisclosureSEC source: 0001209191-20-064581 · doc4.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 02:07 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 19,806 | $60.00 | $1,188,360.00 |
DisclosureSEC source: 0001209191-20-064581 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,194 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2020 Filed Nov 30, 2020 22:11 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 12,152 | $50.00 | $607,600.00 |
DisclosureSEC source: 0001209191-20-060751 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 25, 2020 Filed Nov 25, 2020 22:16 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 12,848 | $50.00 | $642,400.00 |
DisclosureSEC source: 0001209191-20-060558 · doc4.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,152 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.